Omecamtiv mecarbil should target patient subgroups to penetrate crowded HF market, says analyst

14 October 2016
2019_biotech_test_vial_discovery_big

Omecamtiv mecarbil (OM), Cytokinetics’ promising new drug in the chronic heart failure treatment space, will struggle to penetrate the crowded market despite positive results from a recent Phase II study exploring OM’s efficacy in reduced ejection fraction (HF-REF), according to a new analysis.

According to research and consulting firm GlobalData’s most recent heart failure report, the treatment market will be invigorated by a number of exciting new therapies to reach $11.8 billion by 2025. In this way, although OM has a positive efficacy profile, is well tolerated, and boasts a novel mechanism of action through specifically activating cardiac myosin, Cytokinetics and its collaborating partner Amgen (Nasdaq: AMGN) will need to carefully consider which patients to target, and where OM will fit in the HF-REF treatment algorithm.

Elizabeth Hamson, GlobalData’s analyst covering cardiovascular and metabolic disorders, explains: “A key consideration for the companies to address is whether patients will want to add another drug to their already complicated treatment regimens, particularly as OM is taken twice daily. A large proportion of heart failure patients suffer from one or more co-morbidities, for which they take additional medications, so physicians may be reluctant to prescribe them more.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology